重症监护病房内嗜麦芽窄食单胞菌医院获得性肺炎的结局:一项全国性回顾性研究
该全国性回顾性研究纳入2012至2017年法国25个混合ICU中住院期间发生嗜麦芽窄食单胞菌医院获得性肺炎的282例患者,主要终点为院内死亡时间。84%患者在诊断时已插管,插管时间11[5-18]天,SAPS II 47[36-63],院内死亡率49.7%。仅30%的经验性抗菌治疗根据药敏对嗜麦芽窄食单胞菌有效,但延迟恰当抗菌治疗对主要终点无显著影响。联合抗菌治疗(HR=1.27,95%CI [0.88; 1.83],p=0.20)或疗程超过7天(HR=1.06,95%CI [0.6; 1.86],p=0.84)均未显示生存获益。
要点
- 282例ICU获得性嗜麦芽窄食单胞菌HAP患者院内死亡率为49.7%,84%诊断时已插管,插管时间11[5-18]天。
- 经验性抗菌治疗根据药敏仅30%对嗜麦芽窄食单胞菌有效,但延迟恰当抗菌治疗对院内死亡时间无显著影响。
- 联合抗菌治疗较单药治疗无生存获益(HR=1.27,95%CI [0.88; 1.83],p=0.20)。
- 抗菌疗程超过7天较≤7天无生存获益(HR=1.06,95%CI [0.6; 1.86],p=0.84)。
- 单微生物与多微生物嗜麦芽窄食单胞菌HAP的院内死亡无差异(p=0.273),单微生物组诊断前通气时间和ICU住院时间更短(p=0.031和p=0.034)。
适用人群与场景
- 2012至2017年法国25个混合ICU中住院期间发生嗜麦芽窄食单胞菌医院获得性肺炎的成人患者。
- 84%患者在诊断时已插管,插管时间11[5-18]天;SAPS II 47[36-63];14.1%有慢性肺部基础疾病。
研究设计与关键结果
- 全国性回顾性研究,纳入282例ICU住院期间发生嗜麦芽窄食单胞菌HAP的患者,主要终点为院内死亡时间。
- 院内死亡率为49.7%;经验性抗菌治疗根据药敏仅30%对嗜麦芽窄食单胞菌有效。
- 延迟恰当抗菌治疗对主要终点无显著影响。
- 联合抗菌治疗较单药治疗无生存获益(HR=1.27,95%CI [0.88; 1.83],p=0.20)。
- 抗菌疗程超过7天较≤7天无生存获益(HR=1.06,95%CI [0.6; 1.86],p=0.84)。
- 单微生物与多微生物嗜麦芽窄食单胞菌HAP的院内死亡无差异(p=0.273);单微生物组诊断前通气时间和ICU住院时间更短(p=0.031和p=0.034)。
证据类型、等级与局限
- 证据类型:全国性回顾性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于ICU中长期插管、住院时间长的重症患者,出现嗜麦芽窄食单胞菌HAP时,经验性抗菌治疗根据药敏仅30%有效。
- 联合抗菌治疗和超过7天的延长疗程在该研究中均未显示生存获益(HR=1.27,95%CI [0.88; 1.83],p=0.20;HR=1.06,95%CI [0.6; 1.86],p=0.84)。
- 延迟恰当抗菌治疗在该研究中未显著影响院内死亡时间。
指南或共识出处
- clinicaltrials.gov,NCT03506191
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: There is little descriptive data on Stenotrophomonas maltophilia hospital-acquired pneumonia (HAP) in critically ill patients. The optimal modalities of antimicrobial therapy remain to be determined. Our objective was to describe the epidemiology and prognostic factors associated with S. maltophilia pneumonia, focusing on antimicrobial therapy.
METHODS: This nationwide retrospective study included all patients admitted to 25 French mixed intensive care units between 2012 and 2017 with hospital-acquired S. maltophilia HAP during intensive care unit stay. Primary endpoint was time to in-hospital death. Secondary endpoints included microbiologic effectiveness and antimicrobial therapeutic modalities such as delay to appropriate antimicrobial treatment, mono versus combination therapy, and duration of antimicrobial therapy.
RESULTS: Of the 282 patients included, 84% were intubated at S. maltophilia HAP diagnosis for duration of 11 [5-18] days. The Simplified Acute Physiology Score II was 47 [36-63], and the in-hospital mortality was 49.7%. Underlying chronic pulmonary comorbidities were present in 14.1% of cases. Empirical antimicrobial therapy was considered effective on S. maltophilia according to susceptibility patterns in only 30% of cases. Delay to appropriate antimicrobial treatment had, however, no significant impact on the primary endpoint. Survival analysis did not show any benefit from combination antimicrobial therapy (HR = 1.27, 95%CI [0.88; 1.83], p = 0.20) or prolonged antimicrobial therapy for more than 7 days (HR = 1.06, 95%CI [0.6; 1.86], p = 0.84). No differences were noted in in-hospital death irrespective of an appropriate and timely empiric antimicrobial therapy between mono- versus polymicrobial S. maltophilia HAP (p = 0.273). The duration of ventilation prior to S. maltophilia HAP diagnosis and ICU length of stay were shorter in patients with monomicrobial S. maltophilia HAP (p = 0.031 and p = 0.034 respectively).
CONCLUSIONS: S. maltophilia HAP occurred in severe, long-stay intensive care patients who mainly required prolonged invasive ventilation. Empirical antimicrobial therapy was barely effective while antimicrobial treatment modalities had no significant impact on hospital survival.
TRIAL REGISTRATION: clinicaltrials.gov, NCT03506191.
参考来源
- Guerci P, Bellut H, Mokhtari M, et al. Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study. Crit Care. 2019. PMID: 31752976. doi:10.1186/s13054-019-2649-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。